mirdametinib

{
  "id": "MLC-T-ONC-015198",
  "term": "mirdametinib",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.",
  "synonyms": [
    "MEK inhibitor PD0325901",
    "PD-0325901"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mirdametinib/"
}